Aurora Investment Managers LLC. Takes Position in Pfizer Inc. $PFE

Aurora Investment Managers LLC. bought a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 107,664 shares of the biopharmaceutical company’s stock, valued at approximately $2,681,000. Pfizer comprises about 1.5% of Aurora Investment Managers LLC.’s holdings, making the stock its 27th biggest holding.

Other institutional investors have also recently made changes to their positions in the company. Elmwood Wealth Management Inc. increased its position in shares of Pfizer by 15.4% during the 4th quarter. Elmwood Wealth Management Inc. now owns 13,110 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 1,754 shares during the last quarter. Armstrong Advisory Group Inc. lifted its stake in shares of Pfizer by 46.5% in the 4th quarter. Armstrong Advisory Group Inc. now owns 10,484 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 3,328 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Pfizer by 3.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,414,548 shares of the biopharmaceutical company’s stock worth $86,841,000 after acquiring an additional 105,368 shares during the last quarter. Gryphon Financial Partners LLC increased its stake in Pfizer by 13.6% in the 4th quarter. Gryphon Financial Partners LLC now owns 9,305 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 1,117 shares during the period. Finally, Wedmont Private Capital lifted its position in Pfizer by 18.7% in the fourth quarter. Wedmont Private Capital now owns 36,991 shares of the biopharmaceutical company’s stock valued at $935,000 after purchasing an additional 5,825 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. HSBC increased their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the company a “positive” rating in a research report on Tuesday, March 17th. UBS Group initiated coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. Barclays initiated coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price for the company. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.14.

Pfizer Stock Performance

Shares of PFE opened at $26.98 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a 50-day simple moving average of $26.68 and a two-hundred day simple moving average of $25.61. The firm has a market capitalization of $153.41 billion, a PE ratio of 19.84 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the business earned $0.63 EPS. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.